A Phase 4, interventional, open-label trial, investigating the effectiveness of eptinezumab in participants with migraine and previous inadequate response to CGRP-targeting therapies
TITLE:
The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).
MEDICAL CONTION:
Migraine
AGE:
18 Years to 75 Years
SEX/GENDER:
Male & Female